Trial · NCT07894835
The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With Pneumonia
NCT07894835, Not applicable, Recruiting, Far Eastern Memorial Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With Pneumonia. Trials, record NCT07894835. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894835
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With Pneumonia
- NCT number
- NCT07894835
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 84 participants, estimated
- Lead sponsor
- Far Eastern Memorial Hospital
- Conditions
- Pneumonia, Dyspnea
- Interventions
- Sunflower oil inhalation, 1% Linalool inhalation, Wintergreen essential oil inhalation
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Dyspnoea-12 (D-12) Score | Baseline (Day 1 before intervention) and Post-intervention (Day 4 after completion of 3-day intervention) | Assessed using the Chinese version of the Dyspnoea-12 (D-12) questionnaire to measure physical and affective components of dyspnea. The scale consists of 12 items, with each item scored from 0 (none) to 3 (severe), yielding a total score ranging from 0 to 36. Higher scores indicate greater severity of dyspnea. |
| Secondary | Change in Respiratory Rate (RR) | Baseline (Day 1 before intervention) and Post-intervention (Day 4 after completion of 3-day intervention) | Measured by nursing staff using clinical vital sign monitors to record breaths per minute. |
| Secondary | Change in Oxygen Saturation (SpO2) | Baseline (Day 1 before intervention) and Post-intervention (Day 4 after completion of 3-day intervention). | Measured by nursing staff using pulse oximetry monitors to record peripheral capillary oxygen saturation percentage (%). |
| Secondary | Change in Capillary Blood Lactate Level | Baseline (Day 1 before intervention) and Post-intervention (Day 4 after completion of 3-day intervention). | Measured via single-point fingertip blood sampling using THE EDGE Blood Lactate Monitoring System to obtain point-of-care lactate levels (mmol/L). |
| Secondary | Change in Pulmonary Function (FEV1 and PEF) | Baseline (Day 1 before intervention) and Post-intervention (Day 4 after completion of 3-day intervention) | Evaluated using a portable spirometer (MIR Spirodoc) to measure Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). |
| Secondary | Change in Blood and Inflammatory Biomarkers | Within 1 week before intervention and within 1 week after completion of intervention. | Collected from electronic medical records, including complete blood count (white blood cell count \[WBC\], neutrophil percentage, lymphocyte percentage, hemoglobin \[Hgb\]) and C-reactive protein (CRP) levels. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894835
GET https://conductscience.org/api/trials/v1/NCT07894835/registered